/
Dermatology
Psoriasis Vulgaris
18
Pipeline Programs↗
8
Active Trials↗
18
Companies Involved↗
Psoriasis Vulgaris is an emerging landscape with 18 programs across 18 companies. The most active players are Bristol-Myers Squibb, AbbVie, Boehringer Ingelheim. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 1
No programs
Approved
No programs
Analysis
Modality Breakdown
17programs
Monoclonal antibody1059%
Small molecule635%
Protein / enzyme16%
Modality classified for 100% of 18 pipeline programs.
Analysis
Trial Status
83
clinical trials
Completed60 · 72%
Unknown status14 · 17%
Not yet recruiting4 · 5%
Recruiting3 · 4%
Terminated1 · 1%
Enrolling by invitation1 · 1%
Clinical Trials
Trial Activity
83 trials
Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
Recruiting·—·N/A·NCT07320872·60 enrolled
Topical Diacerein in Psoriasis Vulgaris
Not yet recruiting·—·Phase 4·NCT07352306·60 enrolled
Botox Versus Tacrolimus in Psoriasis Vulgaris
Not yet recruiting·—·Phase 4·NCT06203470·60 enrolled
Topical Thymoquinone in Psoriasis Vulgaris
Not yet recruiting·—·N/A·NCT06508372·30 enrolled
Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris
Completed·—·Phase 4·NCT02004574·201 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)